sarah Hughan sits down with Optiscan (ASX:OIL) CEO and managing director Dr Camile Farah to get the short end of the long story on the company’s latest news.
The med-tech company has received ethical clearance to undertake a human study of cancer margins in patients presenting for surgical treatment of breast cancer.
The study will assess its InVue precision surgery imaging platform during surgery to collect imaging data of the surgical cavity after tumour removal.
Tune in to hear Optiscan’s Dr Camile Farah on how InVue works, the breast cancer study, and more.
The Mercury
Optiscan Imaging's managing director and CEO Dr Camile Farah joins Sarah Hughan on * TV to talk about its InVue imaging platform.
stock head
sarah Hughan sits down with Optiscan (ASX:OIL) CEO and managing...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.005(2.33%) |
Mkt cap ! $183.7M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 22.5¢ | 21.0¢ | $33.42K | 152.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 84017 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 48539 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| OIL (ASX) Chart |